 Part A results from the trial of Seelos Therapeutics Incs NASDAQ:SEEL intranasal ketamine product candidate, SLS-002, and the clarity around the timing of the Part B data release call for a change in recommendation, according to Roth Capital. The Seelos Therapeutics Analyst: Jonathan Aschoff upgraded the rating for Seelos Therapeutics from Neutral to Buy and raised the price target from 2.50 to 8. 